Display options
Cite
Ahmed MB, Ismail MI, Meki AR. Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients. Int J Health Sci (Qassim). 2015;9(2):127-39
Ahmed, M. B., Ismail, M. I., & Meki, A. R. (2015). Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients. International journal of health sciences, 9(2), 127-39.
Ahmed, Manal Basyouni, et al. "Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients." International journal of health sciences vol. 9,2 (2015): 127-39.
Ahmed MB, Ismail MI, Meki AR. Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients. Int J Health Sci (Qassim). 2015 Apr;9(2):127-39. PMID: 26309431; PMCID: PMC4538889.
Copy Download .nbib Format: NLM
Share it on

Int J Health Sci (Qassim). 2015 Apr;9(2):127-39.

Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.

International journal of health sciences

Manal Basyouni Ahmed, Maha Imam Ahmed Ismail, Abdel-Raheim M Meki

Affiliations

  1. Department of Biochemistry, Faculty of Medicine, Qassim University, KSA, Permanent address: Medical Biochemistry Dept., Faculty of Medicine, Ain Shams University Cairo, Egypt.
  2. Department of Biochemistry, Faculty of Medicine, Assuit University, Assuit, Egypt.

PMID: 26309431 PMCID: PMC4538889

Abstract

BACKGROUND: It is now realized that insulin resistance plays a principal role in initiating the pathologic manifestations of the metabolic syndrome (MetS).

OBJECTIVES: The aim of this study was to assess the possible role of osteoprotegerin, visfatin and ghrelin in the pathogenesis of MetS among type 2 diabetes mellitus (T2DM).

DESIGN AND METHODS: Serum blood samples were obtained from 116 subjects (39 T2DM; 48 T2DM with MetS; 29 healthy controls). Glycemic status and lipid profile were assessed by enzymatic method. Osteoprotegerin, visfatin, ghrelin and insulin were measured by ELISA method.

RESULTS: Osteoprotegerin and visfatin were significantly higher, while ghrelin was significantly lower in diabetic patients compared to healthy control group (p<0.05). Moreover, Osteoprotegerin and visfatin showed significant higher levels in T2DM patients with MetS than those without MetS (p<0.05). The best cut-off values for the investigated markers were determined by ROC curve. Osteoprotegerin (1.06 ng/mL), visfatin (32.27 ng/mL) and ghrelin (33.65 pg/mL) presented sensitivity of 76%, 92% and 39.1%; respectively and specificity of 41%, 69.2% and 62.9%; respectively, in predicting MetS among T2DM. Among the investigated parameters, Visfatin was the one which predicts MetS among diabetic patients [AUC=0.88, p<0.05].

CONCLUSION: Osteoprotegerin, visfatin and ghrelin might be implicated in the pathogenesis of diabetes. Moreover, osteoprotegerin and visfatin may have additional potential role in the development of the metabolic syndrome. Visfatin was superior among studied parameters in predicting MetS among T2DM.

Keywords: Diabetes; Ghrelin; Insulin Resistance; Osteoprotegerin; Type 2 diabetes mellitus and Metabolic Syndrome; Visfatin

References

  1. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
  2. Metabolism. 2010 May;59(5):742-7 - PubMed
  3. Diabet Med. 1998 Jul;15(7):539-53 - PubMed
  4. Int J Mol Med. 2011 Apr;27(4):607-15 - PubMed
  5. Int J Pept. 2010;2010:null - PubMed
  6. Diab Vasc Dis Res. 2014 Sep;11(5):359-62 - PubMed
  7. Curr Protein Pept Sci. 2009 Feb;10(1):2-7 - PubMed
  8. Nephrol Dial Transplant. 2008 May;23 (5):1621-7 - PubMed
  9. Clin Biochem. 2001 Oct;34(7):583-8 - PubMed
  10. Clin Endocrinol (Oxf). 2008 Dec;69(6):885-93 - PubMed
  11. Cytokine. 2008 Oct;44(1):168-71 - PubMed
  12. Clin Endocrinol (Oxf). 2008 Dec;69(6):878-84 - PubMed
  13. N Engl J Med. 1971 Feb 18;284(7):353-7 - PubMed
  14. Clin Physiol Funct Imaging. 2013 Mar;33(2):122-30 - PubMed
  15. Maturitas. 2010 Sep;67(1):67-71 - PubMed
  16. Lancet. 2005 Sep 24-30;366(9491):1059-62 - PubMed
  17. Ann N Y Acad Sci. 2010 Nov;1212:E1-E19 - PubMed
  18. J Clin Res Pediatr Endocrinol. 2012 Jun;4(2):76-81 - PubMed
  19. Diabetes Res Clin Pract. 2011 Feb;91(2):154-8 - PubMed
  20. Circulation. 2004 May 11;109 (18):2175-80 - PubMed
  21. Diabetes. 2006 Jul;55(7):2126-31 - PubMed
  22. Eur Rev Med Pharmacol Sci. 2011 Jan;15(1):9-14 - PubMed
  23. Metabolism. 2011 Jan;60(1):63-70 - PubMed
  24. J Endocrinol Invest. 2011 Jan;34(1):e12-5 - PubMed
  25. Metabolism. 2010 Jan;59(1):93-9 - PubMed
  26. Eur J Endocrinol. 2008 Mar;158(3):353-9 - PubMed
  27. Metabolism. 2007 Apr;56(4):451-8 - PubMed
  28. BMC Public Health. 2011 Jul 14;11:562 - PubMed
  29. Metabolism. 2007 Sep;56(9):1216-20 - PubMed
  30. Diabetes Metab Res Rev. 2011 Sep;27(6):515-27 - PubMed
  31. Gut. 2005 Dec;54(12 ):1693-8 - PubMed
  32. Peptides. 2011 Nov;32(11):2301-8 - PubMed
  33. Diabetologia. 1985 Jul;28(7):412-9 - PubMed

Publication Types